Abeona Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>AT</div>
ABEO -- USA Stock  

USD 1.86  0.09  4.62%

Abeona Therapeutics PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.66. Receivables Turnover is expected to rise to 30.97 this year, although the value of Net Income Per Employee will most likely fall to (935.3 K). As many baby boomers are still indifferent towards healthcare space, it makes sense to outline Abeona Therapeutics. We will evaluate if Abeona Therapeutics shares are reasonably priced going into September. This post is to show some fundamental factors affecting Abeona Therapeutics' products and services. I will also disclose how it may impact the investing outlook for Abeona Therapeutics in September.
Published over a month ago
View all stories for Abeona Therapeutics | View All Stories
Should you hold on to your Abeona Therapeutics position?
Over 66.0% of Abeona Therapeutics shares are held by institutions such as insurance companies. Institutional ownership of Abeona Therapeutics refers to the amount of Abeona Therapeutics equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Abeona, including its current ownership diagnostics.

How important is Abeona Therapeutics's Liquidity

Abeona Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Abeona Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Abeona Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Abeona Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Abeona Therapeutics, but it might be worth checking our own buy vs. sell analysis

Sale by Sco Capital Partners Llc of 1989 shares of Abeona Therapeutics

Legal trades by Abeona Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Abeona insider trading alert for sale of common stock by Sco Capital Partners Llc, the corporate stakeholder, on 17th of September 2020. This event was filed by Abeona Therapeutics Inc with SEC on 2020-09-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Abeona Therapeutics retains a total of 83.62 Million outstanding shares. Over half of Abeona Therapeutics outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Abeona Therapeutics. Please watch out for any change in the institutional holdings of Abeona Therapeutics as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
 2017 2018 2019 2020 (projected)
Interest Expense8 K11 K400 K431.58 K
Gross Profit837 K3 M2.7 M2.19 M

Ownership Breakdown

Retail Investors
Retail Investors15.78

Our perspective of the latest Abeona Therapeutics slide

Coefficient of variation is down to 1413.16. It may entail a possible volatility slide. As of the 8th of August, Abeona Therapeutics shows the mean deviation of 4.11, and Risk Adjusted Performance of 0.1219. Abeona Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Abeona Therapeutics, which can be compared to its rivals. Please confirm Abeona Therapeutics jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Abeona Therapeutics is priced correctly, providing market reflects its regular price of 2.86 per share. Please also double-check Abeona Therapeutics total risk alpha, which is currently at (0.30) to validate the company can sustain itself at a future point.

Our Final Perspective on Abeona Therapeutics

Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Abeona Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Abeona valuation and our trade advice on Abeona Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Abeona Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Abeona Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com